Brief: Silence Therapeutics FY Operating Loss 35.8 Mln Stg
March 30 (Reuters) - Silence Therapeutics PLC SLN.L :
* FY REVENUE 5.5 MILLION STG VERSUS 200,000 STG YEAR AGO
* SILENCE THERAPEUTICS - FY CASH FLOW FROM OPERATING
ACTIVITIES
£10.8M OUTFLOW (2019: £1.7M INFLOW) AGAINST AN OPERATING LOSS OF
£35.8M (2019: £22.7M)
Source text for Eikon: ID:nRSd9305Ta
Further company coverage: SLN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing